|
1) Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367: 645-8
|
|
|
|
2) Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3: 730-7
|
|
|
|
|
3) Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the hetero-geneity of leukemia-initiating cells. Blood. 2008; 112: 568-75
|
|
|
|
|
|
4) Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood. 2010; 115: 1976-84
|
|
|
|
|
|
5) Martelli MP, Pettirossi V, Thiede C, et al. CD34＋cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood. 2010; 116: 3907-22
|
|
|
|
|
|
6) Ishikawa F, Yoshida S, Saito Y, et al. Chemo-therapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007; 25: 1315-21
|
|
|
|
|
|
7) van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007; 110: 2659-66
|
|
|
|
|
|
8) Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009; 5: 31-42
|
|
|
|
|
|
9) Florian S, Sonneck K, Hauswirth AW, et al. Detection of molecular targets on the surface of CD34＋/CD38- stem cells in various myeloid malignancies. Leuk Lymphoma. 2006; 47: 207-22
|
|
|
|
|
|
10) Hauswirth AW, Florian S, Printz D, et al. Expression of the target receptor CD33 in CD34＋/CD38-/CD123＋ AML stem cells. Eur J Clin Invest. 2007; 37: 73-82
|
|
|
|
|
|
11) Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12: 1167-74
|
|
|
|
|
|
12) Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138: 286-99
|
|
|
|
|
|
13) Hosen N, Park CY, Tatsumi N, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007; 104: 11008-13
|
|
|
|
|
|
14) Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010; 2: 17ra9
|
|
|
|
|
|
15) Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003; 423: 409-14
|
|
|
|
|
|
16) Jamieson CH, Ailles LE, Dylla SJ, et al. Granulo-cyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351: 657-67
|
|
|
|
|
|
17) Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haemato-poietic stem cells. Nature. 2003; 423: 302-5
|
|
|
|
|
|
18) Antonchuk J, Sauvageau G, Humphries RK. HOXB4-induced expansion of adult hemato-poietic stem cells ex vivo. Cell. 2002; 109: 39-45
|
|
|
|
|
|
19) Thorsteinsdottir U, Mamo A, Kroon E, et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood. 2002; 99: 121-9
|
|
|
|
|
|
20) Varnum-Finney B, Xu L, Brashem-Stein C, et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med. 2000; 6: 1278-81
|
|
|
|
|
|
21) Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005; 307: 1101-4
|
|
|
|
|
|
22) Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009; 114: 5034-43
|
|
|
|
|
|
23) Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001; 98: 2301-7
|
|
|
|
|
|
24) Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A. 2002; 99: 16220-5
|
|
|
|
|
|
25) Xu Q, Simpson SE, Scialla TJ, et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003; 102: 972-80
|
|
|
|
|
|
26) Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood. 2005; 106: 4261-8
|
|
|
|
|
|
27) Matsunaga T, Takemoto N, Sato T, et al. Inter-action between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003; 9: 1158-65
|
|
|
|
|
|
28) Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009; 113: 6215-24
|
|
|
|
|
|
29) Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008; 453: 1072-8
|
|
|
|
|
|
30) Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010; 463: 676-80
|
|
|
|
|
|
31) Notta F, Doulatov S, Laurenti E, et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science. 2011; 333: 218-21
|
|
|
|
|
|
32) Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011; 19: 138-52
|
|
|
|
|
|
33) Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002; 415: 536-41
|
|
|
|
|
|
34) Anderson AC, Anderson DE, Bregoli L, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007; 318: 1141-3
|
|
|
|
|
|
35) Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2010; 107: 14733-8
|
|
|
|
|
|
36) McMahan RH, Golden-Mason L, Nishimura MI, et al. Tim-3 expression on PD-1＋ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest. 2010; 120: 4546-57
|
|
|
|
|
|
37) Nakayama M, Akiba H, Takeda K, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009; 113: 3821-30
|
|
|
|
|
|
38) Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005; 6: 1245-52
|
|
|
|
|
|
39) Dekruyff RH, Bu X, Ballesteros A, et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol. 2010; 184: 1918-30
|
|
|
|
|
|
40) Pearson T, Shultz LD, Miller D, et al. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lympho-haematopoietic engraftment. Clin Exp Immunol. 2008; 154: 270-84
|
|
|
|
|